PLK
Os inibidores de quinases Polo-like (PLK) têm como alvo as PLKs, uma família de quinases serina/treonina essenciais para várias fases da divisão celular, incluindo entrada na mitose, montagem do fuso e citocinese. As PLKs são críticas para a execução adequada do ciclo celular, e sua desregulação é frequentemente associada ao câncer. Inibir as PLKs pode induzir parada do ciclo celular e apoptose em células cancerígenas, tornando esses inibidores ferramentas importantes na pesquisa e terapia do câncer. Na CymitQuimica, oferecemos uma gama de inibidores de PLK de alta qualidade para apoiar sua pesquisa em mitose, controle do ciclo celular e oncologia.
Foram encontrados 28 produtos de "PLK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Centrinone
CAS:<p>Centrinone (LCR-263) (LCR-263) is a reversible inhibitor of polo-like kinase 4 (PLK4; Ki:0.16 nM).</p>Fórmula:C26H25F2N7O6S2Pureza:98.76%Cor e Forma:SolidPeso molecular:633.65TTK/PLK1-IN-1
CAS:<p>TTK/PLK1-IN-1 (Formula I) is a dual inhibitor of TTK (threonine tyrosine kinase) and PLK1 (polo-like kinase 1), with IC₅₀ values of 7 nM and 72 nM respectively.</p>Fórmula:C30H33N7O2Pureza:97.39%Cor e Forma:SolidPeso molecular:523.63RP-1664
CAS:<p>RP-1664,PLK4 inhibitor (IC50=3 nM). Disrupts centriole biogenesis. Antitumor activity in breast cancer, neuroblastoma.</p>Fórmula:C23H24F2N8O2SPureza:99.04%Cor e Forma:SoildPeso molecular:514.55PLK1-IN-12
<p>PLK1-IN-12 is a highly selective, orally active PLK1 inhibitor with an IC50 of 20 nM. It demonstrates greater selectivity for PLK1 over PLK2 (IC50: >10000 nM) and PLK3 (IC50: 3953 nM). PLK1-IN-12 exhibits anticancer efficacy across a wide range of cell lines and is applicable to anti-leukemia research.</p>Cor e Forma:Odour SolidPLK1-IN-14
<p>PLK1-IN-14 (Compound Hit-4) is a selective PLK1 inhibitor with an IC50 of 22.61 pM for PLK1, and an IC50 of 0.09 nM for inhibiting the proliferation of DU-145 prostate cancer cells. It is applicable in prostate cancer research.</p>Cor e Forma:Odour SolidSP27
<p>SP27, a selective PROTAC, degrades PLK4 with a DC50 of 19.5 nM and may be utilized in breast cancer research [1].</p>Fórmula:C40H40F2N12O5Pureza:98%Cor e Forma:SolidPeso molecular:806.82PLK1 Protein, Mouse, Recombinant (His)
<p>PLK1 Protein, Mouse, Recombinant (His) is expressed in Baculovirus insect cells with His tag.</p>Cor e Forma:Lyophilized PowderPeso molecular:70.6 kDa (predicted); 65 kDa (reducing conditions)Poloxime
CAS:Poloxime is a hydrolysis product of poloxin and is a non-ATP-competitive Plk1 inhibitor. It also has moderate Plk1 inhibitory activity.Fórmula:C10H13NO2Pureza:98%Cor e Forma:SolidPeso molecular:179.22PLK1 Protein, Human, Recombinant (His)
PLK1 Protein, Human, Recombinant (His) is expressed in Baculovirus insect cells with His tag.Pureza:96.8%Cor e Forma:Lyophilized PowderPeso molecular:70.5 kDa (predicted); 66 kDa (reducing conditions)5-ETHYL-4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDIN-2-YLAMINE
CAS:<p>5-ETHYL-4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDIN-2-YLAMINE targets PLK1.</p>Fórmula:C8H13N3SPureza:99.03%Cor e Forma:SolidPeso molecular:183.27Poloxin
CAS:<p>Poloxin is a non-ATP competitive Polo-like Kinase 1 inhibitor. It targets the polo-box domain (IC50: appr 4.8 μM).</p>Fórmula:C18H19NO3Pureza:99.19%Cor e Forma:SolidPeso molecular:297.35HMN-214
CAS:<p>HMN-214 (IVX-214) is a potent PLK1 inhibitor with an average IC50 of 0.12 μM.</p>Fórmula:C22H20N2O5SPureza:98% - >99.99%Cor e Forma:SolidPeso molecular:424.47TAK-960
CAS:<p>TAK-960 is an orally bioavailable, selective inhibitor of Plks with IC50 values of 0.8, 16.9, and 50.2 nM for Plk1, Plk2, and Plk3, respectively.</p>Fórmula:C27H34F3N7O3Pureza:97.06%Cor e Forma:SolidPeso molecular:561.6Ro3280
CAS:<p>Ro3280 (Ro5203280) is an effective, specific inhibitor of PLK1(IC50=3, Kd=0.09 nM).</p>Fórmula:C27H35F2N7O3Pureza:97.1% - >99.99%Cor e Forma:SolidPeso molecular:543.61GSK461364
CAS:<p>GSK461364 (GSK461364A)(Ki=2.2 nM) inhibits purified Plk1 .The specificity of GSK461364 for Plk1 is more than 1000-fold over Plk2/3.</p>Fórmula:C27H28F3N5O2SPureza:99% - 99.73%Cor e Forma:SolidPeso molecular:543.6MLN0905
CAS:<p>MLN0905 (PLK1 Inhibitor) is an effective PLK1 inhibitor(IC50=2 nM).</p>Fórmula:C24H25F3N6SPureza:97.17% - 98%Cor e Forma:SolidPeso molecular:486.56(1E)-CFI-400437 dihydrochloride
CAS:<p>(1E)-CFI-400437 dihydrochloride (CFI-400437 dihydrochloride) is a selective and potent polo-like kinase 4 (PLK4) inhibitor.</p>Fórmula:C29H30Cl2N6O2Pureza:97.08%Cor e Forma:SolidPeso molecular:565.5HMN-176
CAS:<p>HMN-176 is a stilbene derivative which inhibits mitosis, interfering with polo-like kinase-1 (plk1).</p>Fórmula:C20H18N2O4SPureza:98.92% - 98.99%Cor e Forma:SolidPeso molecular:382.43Ocifisertib(CFI-400945 free base)
CAS:<p>Ocifisertib (CFI-400945 free base) is a potent, selective and orally active inhibitor of polo-like kinase 4.Cost-effective and quality-assured.</p>Fórmula:C33H34N4O3Pureza:98.53% - 99.04%Cor e Forma:SolidPeso molecular:534.65Cyclapolin 9
CAS:<p>Cyclapolin 9: Selective PLK1 inhibitor, IC50 500 nM, ATP-competitive, inactive against other kinases.</p>Fórmula:C9H4F3N3O4SPureza:99.5%Cor e Forma:SolidPeso molecular:307.21Centrinone-B
CAS:Centrinone-B (LCR-323) is a Plk4 inhibitor with potential anticancer activity for the study of triple-negative breast cancer.Fórmula:C27H27F2N7O5S2Pureza:98.71%Cor e Forma:SolidPeso molecular:631.67TC-S 7005
CAS:TC-S 7005 is an effective inhibitor of Polo-like kinases (IC50s: 214 nM, 4 nM and 24 nM for Plk1, Plk2, and Plk3).Fórmula:C21H17N3O3Pureza:99.516%Cor e Forma:SolidPeso molecular:359.38Poloxin-2
CAS:<p>Poloxin-2 is a potent and selective Plk1 PBD inhibitor with anti-tumour activity that reduces the protein level of Plk1 in HeLa cells.</p>Fórmula:C16H15NO3Pureza:99.67%Cor e Forma:SolidPeso molecular:269.3Plogosertib
CAS:<p>Plogosertib (CYC140) is a PLK1 inhibitor with an IC50 value of 3 nM.Plogosertib is antiproliferative and can be used to study solid and hematologic tumors.</p>Fórmula:C34H48N8O3Pureza:99.22% - 99.85%Cor e Forma:SolidPeso molecular:616.797PLK1-IN-11
CAS:<p>PLK1-IN-11 (Cluster 4, 16953209) is a PLK1 inhibitor with an IC50 of 1 μM. It is applicable in research on various cancers such as pancreatic, ovarian, breast, and non-small cell lung cancer.</p>Fórmula:C12H11N5OCor e Forma:SolidPeso molecular:241.249PLK1-IN-5
CAS:<p>PLK1-IN-5, a potent PLK1 inhibitor, has an IC50 of less than 500 nM and demonstrates anticancer effects (WO2008113711A1; compound I-4) [1].</p>Fórmula:C28H39N7O3Cor e Forma:SolidPeso molecular:521.65IIP0943
CAS:<p>IIP0943 is a selective PLK1 (polo-like kinase 1) inhibitor with an IC50 of 5.1 nM for PLK1. It also exhibits inhibitory activity on the proliferation of HCT116 cells, with an IC50 of 0.22 µM. IIP0943 shows potential for research in the field of oncology.</p>Fórmula:C26H28N6O3SCor e Forma:SolidPeso molecular:504.604CD 10899
CAS:<p>CD 10899, a hydroxylated metabolite of Volasertib, is pharmacologically active against Polo-like kinase 1 (PLK1) with an IC50 of 6 nM. Volasertib is an orally active, highly potent, and ATP-competitive PLK1 inhibitor. CD 10899 can be used for cancer research [1].</p>Fórmula:C34H50N8O4Cor e Forma:SolidPeso molecular:634.81
![5-ETHYL-4,5,6,7-TETRAHYDRO-THIAZOLO[5,4-C]PYRIDIN-2-YLAMINE](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2FTM%2Fthumb-webp%2FT8912.webp&w=3840&q=75)
